← LeaderboardsInvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Amplo Biotechnology, Inc.
Towson, MD
$6,157,361
Total funding
2
Grants
Funding over time
peak $3.2M · FY2021–25$5M$3.8M$2.5M$1.3M$0
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$6,157,361 · 2
By mechanism
R44$4,856,116 · 1
R42$1,301,245 · 1
Investigators at Amplo Biotechnology, Inc.
InvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Exposure= the full size of every grant they're on ($1M each).
Rising Stars
First grant in the last 5 yrs
Not enough data
Emerging Leaders
6–10 yrs in
All-Time
Most funded here, all years
Largest grants
Targeted DOK7 gene therapy for Congenital Myasthenic Syndromes$2,999,358
R44 · FY2024 · NS
Targeted DOK7 gene therapy for Congenital Myasthenic Syndromes$1,458,731
R44 · FY2022 · NS
Targeted ColQ gene therapy for Congenital Myasthenic Syndromes$601,044
R42 · FY2025 · NS
Targeted ColQ gene therapy for Congenital Myasthenic Syndromes$493,111
R42 · FY2023 · NS
Targeted DOK7 gene therapy for Congenital Myasthenic Syndromes$253,925
R44 · FY2021 · NS
Targeted ColQ gene therapy for Congenital Myasthenic Syndromes$207,090
R42 · FY2024 · NS
Targeted DOK7 gene therapy for Congenital Myasthenic Syndromes$144,102
R44 · FY2023 · NS